Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders for Inhibikase Therapeutics, Inc., held on June 24, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Atlanta, Georgia.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal One (Approved): Election of two Class II directors to serve until the 2025 annual meeting.
- Roy Freeman, M.D.: 11,443,604 votes for; 574,448 votes withheld; 4,467,473 broker non-votes.
- Paul Grint, M.D.: 11,530,376 votes for; 487,676 votes withheld; 4,467,473 broker non-votes.
- Proposal Two (Not Adopted): Amendment to the Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares. The proposal failed to meet the requisite approval percentage.
- Votes For: 15,007,293
- Votes Against: 1,428,440
- Abstain: 49,792
- Proposal Three (Approved): Ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 16,397,389
- Votes Against: 31,521
- Abstain: 56,614
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- The proposal to increase authorized shares of common stock was rejected by stockholders.
- Roy Freeman, M.D., and Paul Grint, M.D., were successfully elected to the Board of Directors.
- CohnReznick LLP was ratified as the independent auditor for the 2022 fiscal year.
- Broker non-votes were significant for the director elections (approx. 4.47 million) but did not affect the outcome of the other proposals.